image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 12.49
-1.26 %
$ 1.55 B
Market Cap
62.45
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DVAX stock under the worst case scenario is HIDDEN Compared to the current market price of 12.5 USD, Dynavax Technologies Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DVAX stock under the base case scenario is HIDDEN Compared to the current market price of 12.5 USD, Dynavax Technologies Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DVAX stock under the best case scenario is HIDDEN Compared to the current market price of 12.5 USD, Dynavax Technologies Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DVAX

image
$14.5$14.5$14.0$14.0$13.5$13.5$13.0$13.0$12.5$12.5$12.0$12.0$11.5$11.5$11.0$11.0$10.5$10.5$10.0$10.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
277 M REVENUE
19.36%
-4.12 M OPERATING INCOME
88.87%
27.3 M NET INCOME
527.44%
66.5 M OPERATING CASH FLOW
-33.86%
-18 M INVESTING CASH FLOW
88.28%
-102 M FINANCING CASH FLOW
-7360.53%
72 M REVENUE
-10.66%
-1.63 M OPERATING INCOME
-16.19%
7.05 M NET INCOME
-59.93%
53 M OPERATING CASH FLOW
172.31%
23.4 M INVESTING CASH FLOW
251.09%
-98.9 M FINANCING CASH FLOW
-3993.34%
Balance Sheet Dynavax Technologies Corporation
image
Current Assets 849 M
Cash & Short-Term Investments 714 M
Receivables 46.9 M
Other Current Assets 88.2 M
Non-Current Assets 137 M
Long-Term Investments 0
PP&E 60.6 M
Other Non-Current Assets 76.7 M
72.38 %4.76 %8.94 %6.15 %7.78 %Total Assets$986.3m
Current Liabilities 78.6 M
Accounts Payable 9.06 M
Short-Term Debt 0
Other Current Liabilities 69.6 M
Non-Current Liabilities 311 M
Long-Term Debt 250 M
Other Non-Current Liabilities 60.6 M
17.86 %64.25 %15.56 %Total Liabilities$389.5m
EFFICIENCY
Earnings Waterfall Dynavax Technologies Corporation
image
Revenue 277 M
Cost Of Revenue 0
Gross Profit 277 M
Operating Expenses 281 M
Operating Income -4.12 M
Other Expenses -31.4 M
Net Income 27.3 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)277m0277m(281m)(4m)31m27mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-1.49% OPERATING MARGIN
-1.49%
9.85% NET MARGIN
9.85%
4.58% ROE
4.58%
2.77% ROA
2.77%
-0.40% ROIC
-0.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Dynavax Technologies Corporation
image
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 27.3 M
Depreciation & Amortization 8.05 M
Capital Expenditures -6.35 M
Stock-Based Compensation 52.6 M
Change in Working Capital -16 M
Others -26.1 M
Free Cash Flow 60.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Dynavax Technologies Corporation
image
Wall Street analysts predict an average 1-year price target for DVAX of $24.5 , with forecasts ranging from a low of $20 to a high of $29 .
DVAX Lowest Price Target Wall Street Target
20 USD 60.13%
DVAX Average Price Target Wall Street Target
24.5 USD 96.16%
DVAX Highest Price Target Wall Street Target
29 USD 132.19%
Price
Max Price Target
Min Price Target
Average Price Target
30302828262624242222202018181616141412121010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Dynavax Technologies Corporation
image
Sold
0-3 MONTHS
802 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
43.1 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Dynavax Files Preliminary Proxy Statement Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Annual Meeting"). prnewswire.com - 1 week ago
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. zacks.com - 3 weeks ago
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction EMERYVILLE, Calif. , March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions"). prnewswire.com - 1 month ago
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030. seekingalpha.com - 1 month ago
Dynavax to Participate in Upcoming Investor Conferences EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. prnewswire.com - 1 month ago
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2024 Financial Results Conference Call. seekingalpha.com - 1 month ago
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago. zacks.com - 1 month ago
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m. prnewswire.com - 1 month ago
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value. prnewswire.com - 1 month ago
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine instead of pursuing new acquisitions. reuters.com - 1 month ago
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines. benzinga.com - 1 month ago
8. Profile Summary

Dynavax Technologies Corporation DVAX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.55 B
Dividend Yield 0.00%
Description Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Contact 2100 Powell Street, EmeryVille, CA, 94608 https://www.dynavax.com
IPO Date Feb. 19, 2004
Employees 405
Officers Mr. Paul Cox Vice President of Investor Relations & Corporate Communications Dr. Dong Yu Senior Vice President of Research Mr. Eric Frings Vice President, Site Head & MD for Dynavax GmbH Mr. Jeff P. Coon Senior Vice President & Chief Human Resources Officer Mr. Donn Casale Senior Vice President & Chief Commercial Officer Ms. Kelly MacDonald CPA Senior Vice President, Principal Accounting Officer & Chief Financial Officer Dr. Robert Janssen M.D. Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs Mr. Ryan Spencer Chief Executive Officer & Director Mr. John L. Slebir Senior Vice President & General Counsel Mr. David F. Novack President & Chief Operating Officer